Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672055 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
A Phase 2 study of COVID-19 and SARS-CoV-2, sponsored by Vaxart.
- Active
- Registry status
- Phase 2
- Development phase
- 10,400
- Enrollment target
- 20
- Study locations
NCT06672055: Active Phase 2 study of COVID-19 and SARS-CoV-2, sponsored by Vaxart.
NCT06672055 is a Phase 2 study of COVID-19 and SARS-CoV-2 that is active but no longer recruiting, run by Vaxart. The registered enrollment target is 10,400 participants, below the 38,430-participant average among 298 other COVID-19 trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06672055, a Phase 2 study of COVID-19 and SARS-CoV-2, is active but no longer recruiting, sponsored by Vaxart.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.
Conditions Studied
Interventions
- BIOLOGICAL COMIRNATY®
- BIOLOGICAL VXA-CoV2-3.1
- BIOLOGICAL VXA-CoV2-3.3
Study Locations (20)
California
- Elligo Health Research (BTC/ClinEdge) - Core Healthcare Group - Cerritos
- Velocity Clinical Research - Chula Vista (eStudySite - Chula Vista) - Chula Vista
- Avacare - Benchmark Research - SOCAL-Colton - Colton
- Altasciences Los Angeles (Formerly WCCT Global) - Cypress
- Ark Clinical Research - Fountain Valley, CA - Fountain Valley
- Velocity Clinical Research - San Diego (eStudySite - La Mesa) - La Mesa
- Ark Clinical Research - Long Beach, CA - Long Beach
- Velocity Clinical Research (National Research Institute) - Panorama City - Los Angeles
- Northern California Research - Sacramento
- Avacare - Benchmark Research - Sacramento - Sacramento
- Velocity Clinical Research - Gardena - Santa Ana
Arizona
- Avacare - Lenzmeier Family Medicine - Glendale
- Desert Clinical Research - Mesa
- Velocity Clinical Research - MedPharmics - Phoenix - Phoenix
- Foothills Research Center - Phoenix
- Avacare (CCT) - Fiel Family & Sports Medicine - Tempe
Alabama
- Pinnacle Research Group - Anniston
- Core Clinical Trials - Central Alabama Research LLC - Birmingham
- Coastal Clinical Research - Mobile
Arkansas
- Baptist Health Center for Clinical Research - Little Rock - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,400 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What the registry record for NCT06672055 still lists
NCT06672055 is an interventional study that assigns participants to a tested intervention. Its 10,400 participants enrollment target places it among the larger protocols in the corpus, below the 38,430-participant average among 298 other COVID-19 trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which COMIRNATY® is the first listed.
NCT06672055 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06672055 about?
NCT06672055 is a clinical study titled "A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection". The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-1...
What is the current status of trial NCT06672055?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10,400 participants. The study started on 2024-10-08. Estimated completion is 2026-11.
What conditions does trial NCT06672055 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2.
What interventions are being tested in trial NCT06672055?
The interventions under investigation include: COMIRNATY® (BIOLOGICAL), VXA-CoV2-3.1 (BIOLOGICAL), VXA-CoV2-3.3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06672055?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672055 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06672055's enrollment target sits among peer trials
10,400 24th of 298 higher than 275 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07157774 · 10,450 participants · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT06891222 · 10,500 participants
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
- NCT06081517 · 10,600 participants
Evaluating Disparities in Precision Oncology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI